Calcium channel blockers (versus unexposed)

Neonatal death (< 28 days of life)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13969
R54748		 Parazzini - Nifedipine, 1998 Neonatal death (died in the first week of life) 2nd and/or 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 0.98 [0.14;7.04] C 2/132   2/129 4 132
ref
Total 1 studies 0.98 [0.14;7.04] 4 132
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Parazzini - Nifedipine, 1998Parazzini - Nifedipine, 1998 0.98[0.14; 7.04]41320%ROB confusion: lowROB selection: unclearROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0 RCTRCT 0.98[0.14; 7.04]4132 -NAParazzini - Nifedipine, 1998 1 Type of controls unexposed, sickunexposed, sick 0.98[0.14; 7.04]4132 -NAParazzini - Nifedipine, 1998 1 Tags Adjustment   - Randomisation  - Randomisation 0.98[0.14; 7.04]4132 -NAParazzini - Nifedipine, 1998 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 0.98[0.14; 7.04]4132 -NAParazzini - Nifedipine, 1998 1 All studiesAll studies 0.98[0.14; 7.04]4132 -NAParazzini - Nifedipine, 1998 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.98[0.14; 7.04]4132 -NAParazzini - Nifedipine, 1998 10.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period George - NifedipineGeorge - Nifedipine 1.12[0.68; 1.84]0%-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies6 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (DUPLICATE) 3.70[1.15; 11.10]0%-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies4 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION 3.70[1.15; 11.10]0%-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies4 Sridharan (Isradipine)Sridharan (Isradipine) Out of scale0.50[0.00; 99.00]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies-9 Sridharan (Nifedipine)Sridharan (Nifedipine) Out of scale0.40[0.10; 2.50]NA-exposed to other treatment, sickduring pregnancy (anytime or not specified)studies-9 metaPregmetaPreg 0.98[0.14; 7.04]NaN%132--Parazzini - Nifedipine, 1998 10.510.01.0